<html>
<head>PUBMED IDs for TM4SF5</head>
<body bgcolor='#C5F0F2'><h1>TM4SF5</h1><a href='https://pubmed.ncbi.nlm.nih.gov/9479038/'>Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer.</a> March 28  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/12414866/'>Identification of genes associated with the corticotroph phenotype in bronchial carcinoid tumors.</a> November 5  2002<br><a href='https://pubmed.ncbi.nlm.nih.gov/18357344/'>Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma.</a> March 22  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/21328452/'>Proteasome inhibition causes epithelial-mesenchymal transition upon TM4SF5 expression.</a> June 11  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22427965/'>Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers.</a> August 21  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23624388/'>Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model.</a> August 28  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24802189/'>Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma.</a> September 27  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26531872/'>TM4SF5-CTD-2354A18.1-miR-4697-3P may play a key role in the pathogenesis of gastric cancer.</a> January 6  2015<br></body></html>
